Merck Serono initiates phase II study of Anti-PD-L1 antibody in mMCC
mMCC is a rare and aggressive skin cancer lacking effective treatments
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.